MiNK Therapeutics' Q1 net loss narrows slightly

Mink Therapeutics

15/05/2026 12:39

Overview

US cell therapy developer posted Q1 net loss of $2.7 mln, slightly narrower yr/yr

Company ended Q1 with $9.5 mln in cash, after repaying $5.2 mln note and raising $3 mln

Result Drivers

NON-DILUTIVE COLLABORATIONS - Selective collaborations provided external funding to support pipeline expansion while preserving focus on lead programs

DISCIPLINED SPENDING - Company emphasized reduced operating burn and focused advancement of high-priority programs

Company press release: ID:nGNX9mTf3t

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.57
Q1 Net Income
-$2.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Mink Therapeutics Inc is $39.00, about 271.1% above its May 14 closing price of $10.51

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)